Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 26, 2022

SELL
$2.7 - $7.62 $82,277 - $232,204
-30,473 Reduced 4.19%
696,785 $2.39 Million
Q1 2022

Apr 27, 2022

SELL
$6.3 - $8.84 $367,044 - $515,027
-58,261 Reduced 7.42%
727,258 $5.18 Million
Q4 2021

Feb 02, 2022

SELL
$6.02 - $11.43 $538,212 - $1.02 Million
-89,404 Reduced 10.22%
785,519 $6.54 Million
Q3 2021

Oct 25, 2021

SELL
$5.46 - $22.6 $24.1 Million - $99.8 Million
-4,415,042 Reduced 83.46%
874,923 $6.09 Million
Q2 2021

Aug 02, 2021

SELL
$18.46 - $24.36 $12.2 Million - $16.1 Million
-660,153 Reduced 11.09%
5,289,965 $126 Million
Q1 2021

Apr 30, 2021

BUY
$17.66 - $28.92 $2.23 Million - $3.66 Million
126,515 Added 2.17%
5,950,118 $123 Million
Q4 2020

Feb 05, 2021

BUY
$23.25 - $37.73 $6.79 Million - $11 Million
291,933 Added 5.28%
5,823,603 $143 Million
Q3 2020

Oct 30, 2020

SELL
$3.74 - $28.74 $6.99 Million - $53.7 Million
-1,868,575 Reduced 25.25%
5,531,670 $157 Million
Q2 2020

Jul 27, 2020

SELL
$3.04 - $6.2 $3.09 Million - $6.31 Million
-1,018,075 Reduced 12.09%
7,400,245 $35.2 Million
Q1 2020

Apr 27, 2020

BUY
$2.64 - $3.82 $383,056 - $554,270
145,097 Added 1.75%
8,418,320 $30.1 Million
Q4 2019

Jan 31, 2020

BUY
$2.99 - $4.42 $1.83 Million - $2.7 Million
611,260 Added 7.98%
8,273,223 $28.5 Million
Q3 2019

Oct 31, 2019

BUY
$2.29 - $4.16 $6.46 Million - $11.7 Million
2,818,889 Added 58.2%
7,661,963 $30.7 Million
Q2 2019

Jul 29, 2019

BUY
$2.28 - $7.35 $9.22 Million - $29.7 Million
4,041,880 Added 504.48%
4,843,074 $15.6 Million
Q1 2019

May 08, 2019

BUY
$4.83 - $7.21 $3.87 Million - $5.78 Million
801,194 New
801,194 $5.5 Million

Others Institutions Holding MCRB

About Seres Therapeutics, Inc.


  • Ticker MCRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,072,000
  • Market Cap $114M
  • Description
  • Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...
More about MCRB
Track This Portfolio

Track Sumitomo Mitsui Trust Holdings, Inc. Portfolio

Follow Sumitomo Mitsui Trust Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sumitomo Mitsui Trust Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sumitomo Mitsui Trust Holdings, Inc. with notifications on news.